Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: A pilot pharmacokinetic study

Pharmacotherapy

Volumn 28, Issue 7, 2008, Pages 875-882

  Miller, Jodi L ^a   Ashford, J Wesson ^b   Archer, Sanford M ^c   Rudy, Anita C ^e   Wermeling, Daniel P ^d  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d University of Kentucky   (United States)

^e Intranasal Therapeutics Inc   (United States)

Author keywords

Antipsychotics; Drug delivery; Haloperidol; Intranasal delivery; Pharmacokinetics; Psychiatry

Indexed keywords

HALOPERIDOL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; EYE WATERING; FEMALE; HOT FLUSH; HUMAN; LACRIMATION; MALE; MUSCLE TWITCH; NAUSEA; NORMAL HUMAN; NOSE; NOSE IRRITATION; OPEN STUDY; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL; VOLUNTEER;

ADMINISTRATION, INTRANASAL; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HALOPERIDOL; HUMANS; INFUSIONS, INTRAVENOUS; MALE;

EID: 45749138804     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.7.875     Document Type: Article

References (33)

1. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam or both for psychotic agitation? A multicenter prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40.
2. Battaglia J . Pharmacologic management of acute agitation. Drugs 2005;65:1207-22.
3. Bieniek SA, Ownby RL, Penalver A, Dominguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998;18:57-62.
4. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room. Int Clin Psychopharm 1997;12:175-9.
5. Milton GV, Jann MW. Emergency treatment of psychotic symptoms. Clin Pharmacokinet 1995;28:494-504.
6. Moller H, Kissling W, Lang C, Doerr P, Pirke K, Von Zerssen D. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 1982;139:1571-5.
7. Centorrino F, Meyers AL, Ahl J, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol 2007;22:455-62.
8. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 2005;44:1117-33.
9. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone and midazolam. Acad Emerg Med 2005;12:1167-72.
10. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. Introduction, methods and commentary, expert consensus guidelines on the treatment of behavioral emergencies. J Psych Pract 2005;11(suppl 1):1-108.
11. Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008.
12. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, DeGaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics. Clin Pharmacokinet 2007;46:359-88.
13. Eli Lilly, Inc. Zyprexa (olanzapine) package insert. Available from www.fda.gov/cder/foi/label/2004/21253_Zyprexa_lbl.pdf. Accessed October 22, 2007.
14. Janssen Pharmaceutica Products, L.P., Risperdal (risperidone) package insert. Available from www.fda.gov/cder/foi/nda/2003/21- 444_Risperdal_prntlbl.pdf. Accessed October 22, 2007.
15. Bristol-Myers Squibb Company. Abilify (aripiprazole) prescribing information. Available from http://www.fda.gov/cder/foi/label/2007/021436s017, 021713s012,21729s004,021866s004lbl.pdf. Accessed January 7, 2008.
16. Constantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharmaceut 2007;337:1-24.
17. Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery a promising option for orally less efficient drugs. J Control Release 2006;114:15-40.
18. Wolfe TR, Bernstone T. Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases. J Emerg Nurs 2004;30:141-7.
19. Holley FO, Magliozzi JR, Stanski DR, Lombronzo L, Hollister LE. Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 1983;33:477-84.
20. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokin 1999;37:435-56.
21. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of acute psychotic agitation. J Clin Psychiatry 2001;62:153-7.
22. Cressman WA, Bianchine JR, Slotnick VB, Johnson PC, Plostnieks J. Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 1974;7:99-103.
23. McNeil Pharmaceutical. Haldol (haloperidol) package insert. Available from http://www.fda.gov/cder/ogd/rld/15921s75.pdf. Accessed January 7, 2008.
24. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998;6:99-104.
25. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227-63.
26. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
27. Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC. The bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 2001;41:1225-31.
28. Wermeling DP, Record KE, Kelly TH, Archer SM, Clinch T, Rudy AC. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg 2006;103:344-9.
29. Mittal P, Manohar R, Rawat A. Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures. Indian J Pediatr 2006;73975-8.
30. Wolfe T, Macfarlane T. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 2006;24:343-6.
31. Ahmad S, Ellis J, Kamwendo H, et al. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open label trial. Lancet 2006;367:1591-7.
32. Pang T, Hirsch L. Treatment of convulsive and nonconvulsive status epilepticus. Cur Treat Options Neurol 2005;7:247-59.
33. Prasad K, Krishman P, Al-Roomi K, et al. Anticonvulsant therapy for status epilepticus. Br J Clin Pharmacol 2007;63:640-7.